Prognostic Value of Serum Beta-2 Microglobulin in Myelomatosis
Author Information
Author(s): J. Cuzick, E.H. Cooper, I.C.M. MacLennan
Primary Institution: Imperial Cancer Research Fund
Hypothesis
Is serum beta-2 microglobulin a significant prognostic factor in myelomatosis?
Conclusion
Serum beta-2 microglobulin is the most powerful prognostic variable for myelomatosis at presentation.
Supporting Evidence
- Serum beta-2 microglobulin levels were the single most powerful prognostic variable at presentation.
- Multivariate analysis showed that adding haemoglobin levels provided less clinical value.
- Follow-up measurements of serum beta-2 microglobulin were less variable than at presentation.
Takeaway
Doctors can use a blood test for beta-2 microglobulin to help predict how well patients with myelomatosis will do.
Methodology
The study analyzed serum beta-2 microglobulin levels and other variables in 476 patients from a clinical trial.
Limitations
The study may not account for all variables affecting prognosis, and the follow-up time was limited.
Participant Demographics
Patients were part of the Medical Research Council's 4th trial for myelomatosis.
Statistical Information
P-Value
P=0.006
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website